{"id":"methylphenidate-aripiprazole-and-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Anxiety"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a stimulant that blocks the reuptake of dopamine and norepinephrine, increasing their synaptic availability and enhancing attention and executive function. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, providing antipsychotic and mood-stabilizing effects. The combination is used to address both attention deficits and psychotic or mood symptoms in patients who require both therapeutic actions.","oneSentence":"This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:54:46.644Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) with comorbid psychotic or mood symptoms"},{"name":"Schizophrenia or schizoaffective disorder with attention deficits"}]},"trialDetails":[{"nctId":"NCT07024303","phase":"EARLY_PHASE1","title":"Measurement of Treatment Effects","status":"NOT_YET_RECRUITING","sponsor":"Matthew J O'Brien, PhD, BCBA-D","startDate":"2025-06-15","conditions":"Challenging Behavior, Autism Spectrum Disorder","enrollment":20},{"nctId":"NCT05974241","phase":"PHASE4","title":"Irritability in Children With ADHD and Emotion Dysregulation","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2017-04-21","conditions":"Irritable Mood, ADHD","enrollment":36},{"nctId":"NCT03358277","phase":"NA","title":"Aripiprazole Added on for DMDD in Youths With ADHD","status":"COMPLETED","sponsor":"Tri-Service General Hospital","startDate":"2014-11-19","conditions":"Disruptive Mood Dysregulation Disorder","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ritalin/Concerta, Abilify, and combination"],"phase":"marketed","status":"active","brandName":"Methylphenidate, aripiprazole, and combination","genericName":"Methylphenidate, aripiprazole, and combination","companyName":"Tri-Service General Hospital","companyId":"tri-service-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses methylphenidate to increase dopamine and norepinephrine activity, while aripiprazole acts as a dopamine partial agonist to modulate psychotic symptoms and mood. Used for Attention-deficit/hyperactivity disorder (ADHD) with comorbid psychotic or mood symptoms, Schizophrenia or schizoaffective disorder with attention deficits.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}